作者
Tharappel M Anil, Chandrashekaran Harish, Mudigere N Lakshmi, KrishnaReddy Harsha, Mallappa Onkaramurthy, Venkatesh Sathish Kumar, Nitya Shree, Venkatachalaiah Geetha, Gundalmandikal V Balamurali, Aralakuppe S Gopala, Bobbili Madhusudhan Reddy, Madabosse K Govind, Mammen O Anup, Yoganand Moolemath, Marikunte V Venkataranganna, Madanahalli R Jagannath, Baggavalli P Somesh
发表日期
2014/12
期刊
Cardiovascular Diabetology
卷号
13
页码范围
1-14
出版商
BioMed Central
简介
Objectives
AMP activated protein kinase (AMPK) regulates the coordination of anabolic and catabolic processes and is an attractive therapeutic target for T2DM, obesity and metabolic syndrome. We report the anti-hyperglycemic and anti-hyperlipidemic effects of CNX-012-570 is an orally bioavailable small molecule (molecular weight of 530 Daltons) that directly activates AMPK in DIO and db/db animal models of diabetes.
Methods
Activity and efficacy of the compound was tested in cell based as well as cell free systems in vitro. Male C57BL/6 mice fed with high fat diet (HFD) were assigned to either vehicle or CNX-012-570 (3 mg/kg, orally once a day) for 8 weeks (n = 8). Genetically diabetic db/db mice on chow diet were dosed with vehicle control or CNX-012-570 (2.5 mg/kg, orally once a day) for 6 weeks (n = 8).
Results …
学术搜索中的文章
TM Anil, C Harish, MN Lakshmi, KR Harsha… - Cardiovascular Diabetology, 2014